Clinical Trial Update: TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating TT-816 as monotherapy or with a PD-1 inhibitor in patients with advanced cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• TT-816

Snippet

Sponsor: Teon Therapeutics, Inc. | Conditions: Advanced Cancer, Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED